The pharmaceutical industry traditionally relies on a theory-based approach to drug discovery.
- Patients have unmet needs.
- Biologists identify potential targets.
- Chemists create potential solutions.
- Companies screen millions of potential compounds.
- Researchers test dozens of potential ‘hits.’
- A few candidates progress to animal studies.
- A handful of drugs reach human clinical trials.
- Just 1 in 10,000 drugs that begin this process receive FDA approval.
was founded to
improve these odds
DEVELOP
Introducing
- Wet lab data.
- Bench-proven insights.
- Millions of compounds.
MolecuLern is an AI-enabled drug discovery process that leverages empirical/wet lab data-driven models trained on our curated and proprietary library, including physical and virtual synthesis-ready fragments and NCEs, to identify lead molecules targeting any class of protein.
DRUGS
tackles complex challenges in drug development
This proprietary machine-learning platform and extensive compound library result in a dynamic and improved process focused on more efficiently identifying pharmacological solutions to complex biological problems.
DIFFERENTLY
Accelerated AI discovery without sacrificing the integrity of the process.
Putting the human touch on AI-empowered data makes working with MolecuLern truly innovative. This breakthrough results in candidates with drug-like characteristics, reducing development time and costs, and increasing the potential for positive clinical trial outcomes.
Data Library
Curated from millions of compounds, nearly 14,000 NCE’s with drug-like properties, 8.8 million virtual NCEs and 6,000 synthesized fragments, plus PROTAC and Molecular Glues, all supported by algorithms that rapidly identify more than 40 key properties needed for selecting a lead compound.
Dialed-in Experts
Our co-founders have brought more than 20 drugs to the clinic, with more than 150 manuscripts, books and presentations, over 100 patents, and 10 companies founded with multiple exits. This expertise has been used to train MolecuLern to “think” like world-class human ‘drug hunters.’
Direct to Companies
The company is built to flexibly meet a company’s need to discover/develop novel compounds. Whether you are looking to optimize your compound, want to develop a new drug from scratch, or screen our proprietary library, MolecuLern is ready to collaborate.